JY
KLRS

Jeff Yass’s Kalaris Therapeutics KLRS Stock Holding History

Jeff Yass’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-3,961
Closed -$65.6K – 13260
2024
Q2 		$65.6K Sell
3,961
-9,865
-71% -$174K ﹤0.01% 11285
2024
Q1 		$239K Buy
13,826
+3,769
+37% +$61.5K ﹤0.01% 10219
2023
Q4 		$157K Buy
10,057
+9,531
+1,812% +$376K ﹤0.01% 10927
2023
Q3 		$26K Sell
526
-274
-34% -$18.7K ﹤0.01% 11531
2023
Q2 		$62.6K Hold
800
– – ﹤0.01% 11234
2023
Q1 		$72.5K Buy
+800
New +$102K ﹤0.01% 11512
2022
Q1 		– Sell
-1,578
Closed -$470K – 14151
2021
Q4 		$470K Buy
1,578
+91
+6% +$42.2K ﹤0.01% 9380
2021
Q3 		$857K Buy
+1,487
New +$689K ﹤0.01% 7971

Other funds holding KLRS

SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jeff Yass's KLRS Position: Q2 2026 in Review

Jeff Yass reduced its Kalaris Therapeutics (KLRS) stake by 73% in Q2 2026, selling an estimated $200K and leaving 14,221 shares worth $57.9K. The position accounts for ﹤0.01% of the portfolio, ranked #12776.

Jeff Yass first reported a position in KLRS in Q4 2020 and has held it in 20 quarters since. The position peaked at $1.67M in Q1 2021. 57 funds tracked by Wall St. Rank hold KLRS as of Q2 2026.

  • Jeff Yass held 14,221 shares of Kalaris Therapeutics worth $57.9K as of Q2 2026.
  • Jeff Yass sold 38,463 Kalaris Therapeutics shares in Q2 2026, an estimated $200K.
  • Kalaris Therapeutics made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #12776 holding.
  • Jeff Yass first reported a position in Kalaris Therapeutics in Q4 2020 and has held it in 20 quarters since.
  • Jeff Yass's Kalaris Therapeutics position peaked at $1.67M in Q1 2021.
  • 57 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.